• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

献血者原发性巨细胞病毒感染的自然病程。

The natural course of primary cytomegalovirus infection in blood donors.

机构信息

Institute of Transfusion Medicine, University Hospital of Schleswig-Holstein, Lübeck, Germany.

出版信息

Vox Sang. 2010 Jul 1;99(1):24-33. doi: 10.1111/j.1423-0410.2009.01306.x. Epub 2010 Jan 13.

DOI:10.1111/j.1423-0410.2009.01306.x
PMID:20074081
Abstract

BACKGROUND AND OBJECTIVES

As cytomegalovirus (CMV) DNA is frequently detectable in the plasma of recently infected sero-positive blood donors, information concerning primary CMV infection is important for the identification of possibly infectious donors.

MATERIALS AND METHODS

Monitoring of 17 982 donors for CMV antibodies and DNA in plasma identified 14 subjects with ongoing primary CMV infection. Thirteen donors were interrogated for possible sources of infection and CMV-related symptoms, and monitored for CMV antigens, CMV DNA in plasma, leucocytes and urine, course of IgG and IgM antibodies as well as markers of systemic infection and parameters of organ function.

RESULTS

CMV antigens and DNA were detectable in peripheral blood for up to 54 and 269 days respectively. Clearance of CMV DNA from blood correlated with clearance of IgM antibodies, development of IgG antibodies against the membrane glycoprotein gB and development of high avidity IgG antibodies. Eighty-five percent of subjects with primary CMV infection, but even 69% of matched controls reported possibly CMV-related symptoms. Sixty-two and 23%, respectively, had contact with possible sources of infection. One donor developed a febrile illness accompanied by increased levels of CMV DNA in peripheral blood 2 to 3 weeks after seroconversion. In other donors, neither markers of systemic infection nor parameters of organ function correlated with the course of CMV DNA and antigens.

CONCLUSION

Potentially infectious donors can be identified by measuring CMV DNA, IgM antibodies or avidity of IgG antibodies. Alternatively, blood products donated during the first year after seroconversion should not be used for immunocompromised patients.

摘要

背景与目的

由于巨细胞病毒(CMV)DNA 在新近感染的血清阳性献血者的血浆中经常可检测到,因此有关原发性 CMV 感染的信息对于识别可能具有传染性的献血者非常重要。

材料与方法

对 17982 名献血者进行 CMV 抗体和血浆 DNA 监测,发现 14 例正在进行原发性 CMV 感染的患者。对 13 名献血者进行了可能感染源和 CMV 相关症状的调查,并对 CMV 抗原、血浆、白细胞和尿液中的 CMV DNA、IgG 和 IgM 抗体的消长以及全身性感染的标志物和器官功能参数进行了监测。

结果

CMV 抗原和 DNA 分别在周围血液中可检测到长达 54 和 269 天。从血液中清除 CMV DNA 与清除 IgM 抗体、针对膜糖蛋白 gB 的 IgG 抗体的产生以及高亲和力 IgG 抗体的产生相关。85%的原发性 CMV 感染患者,甚至 69%的匹配对照组均报告有疑似 CMV 相关症状。分别有 62%和 23%的患者与可能的感染源接触。1 名患者在血清转换后 2 至 3 周时发生伴有外周血 CMV DNA 水平升高的发热性疾病。在其他供者中,全身性感染的标志物或器官功能参数均与 CMV DNA 和抗原的消长无关。

结论

可通过测量 CMV DNA、IgM 抗体或 IgG 抗体的亲和力来识别具有潜在传染性的供者。或者,不应将血清转换后 1 年内捐献的血液制品用于免疫功能低下的患者。

相似文献

1
The natural course of primary cytomegalovirus infection in blood donors.献血者原发性巨细胞病毒感染的自然病程。
Vox Sang. 2010 Jul 1;99(1):24-33. doi: 10.1111/j.1423-0410.2009.01306.x. Epub 2010 Jan 13.
2
Primary cytomegalovirus infection in an outpatient setting--laboratory markers and clinical aspects.门诊环境中的原发性巨细胞病毒感染——实验室指标与临床情况
Infection. 2003 Oct;31(5):318-23. doi: 10.1007/s15010-003-3129-y.
3
Primary cytomegalovirus infection in patients with Guillain-Barré syndrome.吉兰-巴雷综合征患者的原发性巨细胞病毒感染
J Neuroimmunol. 2007 Feb;183(1-2):214-9. doi: 10.1016/j.jneuroim.2006.11.006. Epub 2006 Dec 20.
4
High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion.献血者血浆样本中巨细胞病毒DNA的高流行率与血清转化有关。
Transfusion. 2007 Nov;47(11):1972-83. doi: 10.1111/j.1537-2995.2007.01420.x.
5
Recognition of cytomegalovirus clinical isolate antigens by sera from cytomegalovirus-negative blood donors.巨细胞病毒阴性献血者血清对巨细胞病毒临床分离株抗原的识别。
Transfusion. 2004 Jul;44(7):1059-66. doi: 10.1111/j.1537-2995.2004.03292.x.
6
Seroprevalence of cytomegalovirus among voluntary blood donors in Delhi, India.印度德里自愿献血者中巨细胞病毒的血清流行率。
J Health Popul Nutr. 2002 Dec;20(4):348-51.
7
Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding.在健康年轻女性疫苗临床试验期间对巨细胞病毒感染的检测:血清转化和病毒脱落
J Clin Virol. 2006 Mar;35(3):338-42. doi: 10.1016/j.jcv.2005.09.020. Epub 2006 Jan 4.
8
[Cytomegalovirus diagnosis in blood donors and risk patients].[献血者和高危患者的巨细胞病毒诊断]
Beitr Infusionsther. 1990;26:37-9.
9
A serological testing algorithm for the diagnosis of primary CMV infection in pregnant women.一种用于诊断孕妇原发性巨细胞病毒感染的血清学检测算法。
Prenat Diagn. 2004 Nov;24(11):861-3. doi: 10.1002/pd.1001.
10
Prevalence of transfusion associated infections in multitransfused children in relation to mandatory screening of HIV in donated blood.多次输血儿童中输血相关感染的患病率与献血中HIV强制筛查的关系
Southeast Asian J Trop Med Public Health. 1997 Dec;28(4):699-706.

引用本文的文献

1
Cytomegalovirus seroprevalence among blood donors: a systematic review and meta-analysis.献血者巨细胞病毒血清流行率:系统评价和荟萃分析。
J Int Med Res. 2021 Aug;49(8):3000605211034656. doi: 10.1177/03000605211034656.
2
Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.经输血传播的巨细胞病毒:血液成分处理过程中游离病毒的行为。对瑞士不稳定血液成分安全性的研究。
Blood Transfus. 2020 Nov;18(6):446-453. doi: 10.2450/2020.0241-19. Epub 2020 Feb 28.
3
Postnatal cytomegalovirus infection: a pilot comparative effectiveness study of transfusion safety using leukoreduced-only transfusion strategy.
产后巨细胞病毒感染:一项采用仅白细胞滤除输血策略的输血安全性初步比较有效性研究。
Transfusion. 2016 Aug;56(8):1945-50. doi: 10.1111/trf.13605. Epub 2016 Apr 15.
4
Systematic Evaluation of Different Nucleic Acid Amplification Assays for Cytomegalovirus Detection: Feasibility of Blood Donor Screening.用于巨细胞病毒检测的不同核酸扩增检测方法的系统评价:献血者筛查的可行性
J Clin Microbiol. 2015 Oct;53(10):3219-25. doi: 10.1128/JCM.01091-15. Epub 2015 Jul 22.
5
Prevention of Transfusion-Transmitted Cytomegalovirus Infections: Which is the Optimal Strategy?预防输血传播的巨细胞病毒感染:哪种是最佳策略?
Transfus Med Hemother. 2014 Feb;41(1):40-4. doi: 10.1159/000357102. Epub 2013 Dec 19.
6
Alternative blood products and clinical needs in transfusion medicine.替代血液制品与输血医学的临床需求。
Stem Cells Int. 2012;2012:639561. doi: 10.1155/2012/639561. Epub 2012 Apr 8.
7
Cytomegalovirus-induced immunopathology and its clinical consequences.巨细胞病毒诱导的免疫病理学及其临床后果。
Herpesviridae. 2011 Apr 7;2(1):6. doi: 10.1186/2042-4280-2-6.